Janet Eary
Download
1 / 21

STATISTICAL RISK ANLAYSIS FOR CLINICAL OUTCOMES USING MID-THERAPY FDG PET IN SARCOMA PATIENTS - PowerPoint PPT Presentation


  • 125 Views
  • Uploaded on

Janet Eary 1 , Janet O'Sullivan 3 , Finbarr O'Sullivan 3 , E. U. Conrad 2 1. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States. 2. Orthopedics, University of Washington, Seattle, WA, United States. 3. Statistics, University College Cork, Cork, Ireland.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'STATISTICAL RISK ANLAYSIS FOR CLINICAL OUTCOMES USING MID-THERAPY FDG PET IN SARCOMA PATIENTS' - miron


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Statistical risk anlaysis for clinical outcomes using mid therapy fdg pet in sarcoma patients

Janet Eary1, Janet O'Sullivan3, Finbarr O'Sullivan3, E. U. Conrad21. Nuclear Medicine/Radiology, University of Washington, Seattle, WA, United States. 2. Orthopedics, University of Washington, Seattle, WA, United States. 3. Statistics, University College Cork, Cork, Ireland

STATISTICAL RISK ANLAYSIS

FOR CLINICAL OUTCOMES USING MID-THERAPY FDG PET IN SARCOMA PATIENTS


Uw soft tissue sarcoma treatment protocol
UW Soft Tissue Sarcoma Treatment Protocol

  • Large Intermediate and High grade Tumors

  • pre-resection 4 chemotherapy cycles

  • Tumor resection

  • 4 additional cycles of chemotherapy

  • 3 FDG PET scans to monitor response


Statistical risk anlaysis for clinical outcomes using mid therapy fdg pet in sarcoma patients

2-fluoro-2-deoxy-D-glucose

18FDG is the most important PET procedure

  •  FDG reflects altered tissue metabolism

More than just “grading” images.



High grade sarcoma heterogeneous response to chemotherapy
High Grade Sarcoma: Heterogeneous Response to Chemotherapy


Study design analysis
: Study : Design : Analysis :

  • Aims: determine the value of the mid-therapy FDG PET scan for risk assessment for outcome

  • Hypothesis: the mid-therapy FDG PET scan will add predictive value to outcome prediction

  • Methods:

    Prospective study

    Univariate, and multivariate analyses with Cox proportional Hazards analysis, and models for variables for data reduction

    Creation of clinical risk scenarios for different sets of clinical variable combinations


Overall survival univariate models
Overall Survival (Univariate Models)


Overall survival reduced model
Overall Survival (reduced model)





Survival reduced model
Survival (reduced model)

Progression-free Survival

Local Progression-free Survival

Overall Survival


Survival risk multivariate model
Survival Risk (multivariate model)

Truncal tumors

Extremity tumors


Local progression free survival multivariate model
Local Progression-free Survival(Multivariate model)

Truncal tumors

Extremity tumors


Fdg pet risk assessment in sarcoma
FDG PET Risk Assessment in Sarcoma

Conclusions:

  • The mid-therapy scan provides additional information for risk assessment based on FDG PET and clinical variables

  • In addition to overall and progression-free survival, local recurrence risk can be assessed

  • Reduced Hazards and multivariate models for risk assessments provide clinically useful data on an individual patient.

    Future Directions:

  • Comparison/inclusion of other risk assessment models into these analysis results

  • Descriptions of tumor subtype and specific responses to therapy types.

  • Use of tumor image regional analysis to assess areas at risk for local recurrence and metastases


Support your local molecular imaging center thanks

Support your local Molecular Imaging Center !(thanks.)


Progression free survival u nivariate models
Progression-Free Survival (univariate models)



Progression free survival multivariate model
Progression-free Survival(Multivariate model)

Truncal Tumors

Extremity Tumors


Survival risk
Survival Risk

Survival- extremity tumors

Survival- truncal tumors